COMMUNIQUÉS West-GlobeNewswire

ABLYNX TO PRESENT AT THE 36th ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
04/01/2018
GHENT, Belgium, 4 January 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced that it will present at the 36th Annual J.P. Morgan Healthcare Conference on Monday 8 January 2018 at 09:30 a.m. Pacific [...]
Targovax announces that ONCOS-102 generates immune activation in checkpoint inhibitor refractory melanoma patients
04/01/2018
Oslo, Norway, 4 January 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces immune activation data in the first four patients [...]
AVACOPAN CONDITIONAL MARKETING AUTHORIZATION APPLICATION ACCEPTED FOR REGULATORY REVIEW BY EUROPEAN MEDICINES AGENCY
04/01/2018
Conditional marketing authorization application for treatment of patients with ANCA-associated vasculitis validated for start of procedure by EMA Significant milestone further strengthens Kidney Health Alliance [...]
VELTASSA® APPROVED FOR MARKETING IN SWITZERLAND FOR THE TREATMENT OF HYPERKALAEMIA
04/01/2018
Klicken Sie hier für Deutsch Veuillez cliquer ici pour français SWISSMEDIC HAS APPROVED PATIROMER TO BE MARKETED IN SWITZERLAND AS VELTASSA ® FOR THE TREATMENT OF HYPERKALAEMIA (ELEVATED SERUM POTASSIUM LEVELS) IN [...]
Atara Biotherapeutics Announces Pricing of Public Offering of Common Stock
04/01/2018
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA ), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, [...]
Helius Medical Technologies Announces Planned Five-for-One Reverse Stock Split
04/01/2018
NEWTOWN, Pa., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (TSX: HSM ) (TSX:HSM.WT) (OTCQB:HSDT) (“Helius” or the “Company”), a medical technology company focused on neurological wellness, [...]
INC Research/inVentiv Health Announces CFO Transition
03/01/2018
RALEIGH, N.C., Jan. 03, 2018 (GLOBE NEWSWIRE) -- INC Research/inVentiv Health (Nasdaq: INCR ), the only fully integrated biopharmaceutical solutions organization, today announced that Greg Rush is stepping down as Chief [...]
Skyline Medical Provides Sales Update on the STREAMWAY System
03/01/2018
MINNEAPOLIS, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Skyline Medical Inc . (NASDAQ: SKLN ) (“Skyline” or the “Company”), today announced an update on commercial activities for its FDA-approved STREAMWAY ® System for automated [...]
Tabula Rasa HealthCare Engaged to Provide Opioid Education and Interventions to Physicians with Patients at High-Risk for Unintentional Misuse
03/01/2018
MOORESTOWN, N.J., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc . (“TRHC”) (NASDAQ: TRHC ), a healthcare technology company optimizing medication safety by deploying new medication risk mitigation [...]
MPX Bioceutical Announces Beth Stavola Appointed to New Jersey Cannabis Industry Association Board of Trustees
03/01/2018
TORONTO, Jan. 03, 2018 (GLOBE NEWSWIRE) -- MPX Bioceutical Corporation (the “ Company ” or “ MPX ”) (CSE:MPX) (OTC:MPXEF) today announced that Beth Stavola, Chief Operating Officer, and a Director of MPX, has been [...]
Dova Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
03/01/2018
DURHAM, N.C., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA ) today announced that Alex Sapir, President and Chief Executive Officer, will present a company overview at the J.P. Morgan 36 th [...]
Zynerba Pharmaceuticals Provides 2018 Clinical and Corporate Update
03/01/2018
- Focusing Strategy on Rare and Near-Rare Neurological and Psychiatric Disorders - - Pediatric Neurologist Liza Squires, M.D. Joins as Chief Medical Officer - - Conference Call to be Held at 8:30 AM Tomorrow, January 4 [...]
MyoKardia to Present at 36th Annual J.P. Morgan Healthcare Conference
03/01/2018
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK ), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable [...]
Ascendis Pharma Announces Completion of Target Enrollment in Phase 3 Trial of TransCon Growth Hormone for Pediatric Growth Hormone Deficiency
03/01/2018
COPENHAGEN, Denmark, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND ), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare [...]
Insmed Announces Additional Data from ALIS (Amikacin Liposome Inhalation Suspension) Phase 3 Clinical Program for Adult Patients with Treatment Refractory NTM Lung Disease Caused by MAC and Reports Progress with Commercial Preparations
03/01/2018
Interim results from INS-312 show that 28% of patients who previously received 6 months of guideline based therapy (GBT) alone achieved culture conversion following addition of ALIS to therapy, consistent with data from [...]
Prothena to Participate in the 36th Annual J.P. Morgan Healthcare Conference
03/01/2018
DUBLIN, Ireland, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ: PRTA ), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel therapies in [...]
Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA® (aflibercept)
03/01/2018
CAMBRIDGE, Mass., HERTFORDSHIRE, United Kingdom and PITTSBURGH, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA ) and Mylan N.V. (NASDAQ: MYL ) (TASE: MYL ) today announced the development [...]
Five Prime Therapeutics Submits Investigational New Drug Application for Novel B7-H4 Antibody FPA150
03/01/2018
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq: FPRX ), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today [...]
Dova Pharmaceuticals Provides Update on Development Strategy for Avatrombopag in Immune Thrombocytopenic Purpura (ITP) and Chemotherapy-Induced Thrombocytopenia (CIT)
03/01/2018
Supplemental NDA for ITP to be submitted in the second half of 2018 Phase 3 Clinical Trial for CIT to begin in the second quarter of 2018 DURHAM, N.C., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Following two separate meetings [...]

Pages